Effect of trimethoprim-sulphamethoxazole in Langerhans' cell histiocytosis: preliminary observations.
Twenty-three children with Langerhans' cell histiocytosis (LCH) have been treated with trimethoprim-sulphamethoxazole (T-S) in a 4-year period. The children are classified in two main groups according to the extent of their disease. Group A includes 16 children with single system disease and group B, seven children with multisystem disease. All patients were treated for 4 weeks to 3 months. The results of treatment are evaluated in terms of response in individual organs involved. All children with single system disease had a good response to the drug. Children with multisystem disease had a good response to some organs but a poorer outcome for the lungs and for the blood. These patients did not respond even to conventional chemotherapy.
Tzortzatou-Stathopoulou
F
F
First Department of Pediatrics, University of Athens, Agia Sophia Children's Hospital, Greece.
Xaidara
A
A
Mikraki
V
V
Moschovi
M
M
Arvanitis
D
D
Ageloyianni
P
P
Prodromou
P
P
D002648:Child; D002675:Child, Preschool; D005260:Female; D006646:Histiocytosis, Langerhans-Cell / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007223:Infant; D008297:Male; D010306:Parotid Gland / Q000000981:diagnostic imaging; D011859:Radiography; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use*
D015662:Trimethoprim, Sulfamethoxazole Drug Combination